GlassScriptPhysician profile
Roldan Cabret
NPI 1336170521
$2,918.00
in general payments reported to CMS, 2019-2025
18 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $177 · 2021: $576 · 2022: $350 · 2023: $408 · 2024: $307 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,132.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $697.81 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $583.42 | 2019-2023 | Lokelma |
| Janssen Pharmaceuticals, INC | $438.49 | 2019-2024 | Xarelto, Invokana |
| E.R. Squibb & Sons, L.L.C. | $324.52 | 2019-2025 | Eliquis |
| Pbg Puerto Rico LLC | $152.77 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.23 | 2019-2021 | |
| Boston Scientific Corporation | $128.89 | 2025 | General - Therapies, General - Brady |
| Viatris Specialty LLC | $112.58 | 2025 | Yupelri |
| Sanofi-Aventis U.S. LLC | $55.15 | 2021-2022 | |
| Mylan Specialty L.P. | $50.93 | 2021-2024 | Yupelri |
| Glaxosmithkline, LLC. | $43.30 | 2019-2020 | |
| Bayer Puerto Rico INC. | $41.30 | 2023-2024 | Kerendia |
| Eli Lilly Export S.A. Puerto Rico Branch | $40.00 | 2021 | |
| Shionogi INC | $26.65 | 2025 | Fetroja |
| Novartis Pharmaceuticals Corporation | $25.00 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22.04 | 2023 | Synthroid |
| Merck Sharp & Dohme LLC | $19.96 | 2019 | |
| Mylan LLC | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roldan Cabret listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.